Germany · Delayed Price · Currency is EUR Adicet Bio Company Description
Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States.
It offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients.
The company’s lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the potential treatment of autoimmune diseases and relapsed/refractory B-cell non-hodgkin’s lymphoma.
It also develops ADI-270, an armored gamma delta CAR T cell product candidate to treat multiple CD70+ solid tumor and hematological malignancies indications, with renal cell carcinoma.
The company was founded in 2014 and is based in Boston, Massachusetts.
| Country | United States |
| Founded | 2014 |
| Industry | Biological Products, Except Diagnostic Substances |
| Employees | 152 |
| CEO | Chen Schor |
Contact Details
Address: 131 Dartmouth Street Boston, Delaware 02116 United States | |
| Phone | 650 503 9095 |
| Website | adicetbio.com |
Stock Details
| Ticker Symbol | 1IJA |
| Exchange | Frankfurt Stock Exchange |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Chen Schor | Chief Executive Officer |
| Brian Harvey | Chief Financial Officer |